Position: Chief Scientific Officer (since 1 January 2019) 

Number of shares in Navamedic ASA:  627,000 

Year of birth:  1963 

Experience:  

Before joining Navamedic Bratvedt served as Chief Scientific Officer in Weifa ASA. Bratvedt has extensive pharmaceutical experience from executive and professional positions at Weifa ASA, responsible for regulatory strategies, project management and innovation processes, quality assurance and pharmacovigilance. 

Education: 

Bratvedt holds a master’s degree (MSc) in Pharmacy.